Publications by authors named "Torsten Zimmermann"

Claim this Profile
S
Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study.
Andreas Stahl, Noriyuki Azuma, Wei-Chi Wu, Domenico Lepore, Emine Sukgen, Torsten Zimmermann

Eye (Lond)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study.
Andreas Stahl, Noriyuki Azuma, Wei-Chi Wu, Domenico Lepore, Emine Sukgen, Torsten Zimmermann

Eye (Lond)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women.
Hongzhong Liu, Ji Jiang, Zhaozhao Chen, Yunhui Zhang, Jinyi Li, Torsten Zimmermann

Clin Pharmacol Drug Dev· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive-A randomized controlled trial.
Marcus-Hillert Schultze-Mosgau, Barbara Schütt, Corinna Draeger, Manuela Casjens, Stephanie Loewen, Torsten Zimmermann

Br J Clin Pharmacol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study.
Niladri Chattopadhyay, Kai Riecke, Sandra Ligges, Torsten Zimmermann, Atef Halabi

Br J Clin Pharmacol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases.
Peter K Kaiser, Laurent Kodjikian, Jean-Francois Korobelnik, Julia Winkler, Albert Torri, Torsten Zimmermann

BMJ Open Ophthalmol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Developing Regorafenib Eye drops for neovascular Age-related Macular degeneration (DREAM) study: an open-label phase II trial.
Antonia M Joussen, Sebastian Wolf, Peter K Kaiser, David Boyer, Thomas Schmelter, Torsten Zimmermann

Br J Clin Pharmacol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans.
Niladri Chattopadhyay, Tobias Kanacher, Manuela Casjens, Sebastian Frechen, Sandra Ligges, Torsten Zimmermann

Br J Clin Pharmacol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential.
Marcus-Hillert Schultze-Mosgau, Joachim Höchel, Olaf Prien, Torsten Zimmermann, Ashley Brooks

Clin Pharmacokinet· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topical administration of regorafenib eye drops: phase I dose-escalation study in healthy volunteers.
Torsten Zimmermann, Joachim Höchel, Michael Becka, Michael K Boettger, Beate Rohde

Br J Clin Pharmacol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer's disease patients.
Andrea Varrone, Patrik Mattsson, Anton Forsberg, Akihiro Takano, Sangram Nag, Torsten Zimmermann

Eur J Nucl Med Mol Imaging· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106.
Akihiro Takano, Fredrik Piehl, Jan Hillert, Andrea Varrone, Sangram Nag, Torsten Zimmermann

EJNMMI Res· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women.
Hartmut Blode, Susan Zeun, Susanne Parke, Torsten Zimmermann, Beate Rohde

Contraception· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand [18F]FEDAA1106: a human whole-body PET study.
Akihiro Takano, Balázs Gulyás, Andrea Varrone, Per Karlsson, Nils Sjoholm, Torsten Zimmermann

Eur J Nucl Med Mol Imaging· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
Henryk Barthel, Julia Luthardt, Georg Becker, Marianne Patt, Eva Hammerstein, Torsten Zimmermann

Eur J Nucl Med Mol Imaging· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties.
Ulrich Baumann, Malcolm King, Ernst M App, Shusheng Tai, Armin König, Torsten Zimmermann

Can Respir J· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis